Monoclonal antibody A717
Alternative Names: A 717; HuA717; HuA717 scFvLatest Information Update: 08 May 2003
Price :
$50 *
At a glance
- Originator Exocell
- Developer Glycadia
- Class Monoclonal antibodies
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic complications
Most Recent Events
- 08 May 2003 No development reported - Preclinical for Diabetic complications in USA (unspecified route)
- 22 Jul 1996 Exocell has a US patent to develop monoclonal antibody A717 for kidney disease and other complications of diabetes
- 22 Jul 1996 Preclinical development for Diabetic complications in USA (Unknown route)